Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/21811
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDespierre, Evelyn
dc.contributor.authorVergote, Ignace
dc.contributor.authorAnderson, Ryan
dc.contributor.authorCoens, Corneel
dc.contributor.authorKatsaros, Dionyssios
dc.contributor.authorHirsch, Fred R
dc.contributor.authorBoeckx, Bram
dc.contributor.authorVarella-Garcia, Marileila
dc.contributor.authorFerrero, Annamaria
dc.contributor.authorRay-Coquard, Isabelle
dc.contributor.authorBerns, Els M J J
dc.contributor.authorCasado, Antonio
dc.contributor.authorLambrechts, Diether
dc.contributor.authorJimeno, Antonio
dc.date.accessioned2019-06-28T13:24:42Z-
dc.date.available2019-06-28T13:24:42Z-
dc.date.issued2015-12
dc.identifier.citationTarget Oncol.2015 Dec;(10)4:583-96
dc.identifier.urihttps://hdl.handle.net/20.500.12530/21811-
dc.description.abstractIn this work, we aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarkers in patients with ovarian cancer who were treated within the phase III randomized European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG) 55041 study comparing erlotinib with observation in patients with no evidence of disease progression after first-line platinum-based chemotherapy.
dc.language.isoeng
dc.rightsopenAccess-
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBiomarkers, Tumor
dc.subject.meshDisease Progression
dc.subject.meshDisease-Free Survival
dc.subject.meshErbB Receptors
dc.subject.meshErlotinib Hydrochloride
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshMutation
dc.subject.meshOrganoplatinum Compounds
dc.subject.meshOvarian Neoplasms
dc.subject.meshProtein Kinase Inhibitors
dc.subject.meshProtein Kinases
dc.titleEpidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.
dc.typeArtículo
dc.identifier.pubmedID26004768
dc.format.volume10
dc.format.page583-96
dc.identifier.e-issn1776-260X
dc.identifier.journalTargeted oncology
dc.identifier.doi10.1007/s11523-015-0369-6
dc.format.number4
dc.identifier.pmcPMC4661131
dc.pubmedtypeClinical Trial, Phase III
dc.pubmedtypeJournal Article
dc.pubmedtypeRandomized Controlled Trial
dc.pubmedtypeResearch Support, N.I.H., Extramural
dc.pubmedtypeResearch Support, Non-U.S. Gov't
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. Clínico San Carlos > Artículos

Files in This Item:
File Description SizeFormat 
PMC4661131.pdf1.06 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.